ProQR Therapeutics NV (NASDAQ:PRQR) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 985,408 shares, an increase of 60.6% from the October 15th total of 613,551 shares. Currently, 3.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 254,800 shares, the days-to-cover ratio is currently 3.9 days.
Shares of PRQR stock opened at $19.08 on Friday. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $817.59 million, a P/E ratio of -9.84 and a beta of 0.54. ProQR Therapeutics has a one year low of $2.75 and a one year high of $24.00.
ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.10. Research analysts expect that ProQR Therapeutics will post -1.38 earnings per share for the current fiscal year.
Several analysts recently commented on PRQR shares. Zacks Investment Research raised ProQR Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research note on Thursday, August 9th. HC Wainwright set a $20.00 price target on ProQR Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 9th. Chardan Capital reaffirmed a “buy” rating and issued a $9.00 price target on shares of ProQR Therapeutics in a research note on Monday, August 13th. ValuEngine lowered ProQR Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 30th. Finally, Evercore ISI started coverage on ProQR Therapeutics in a research note on Tuesday, September 18th. They issued an “outperform” rating and a $35.00 price target on the stock. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. ProQR Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $18.00.
Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. raised its position in ProQR Therapeutics by 519.0% in the 1st quarter. JPMorgan Chase & Co. now owns 33,425 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 28,025 shares during the last quarter. Millennium Management LLC bought a new position in ProQR Therapeutics in the 2nd quarter valued at $1,426,000. Ardsley Advisory Partners bought a new position in ProQR Therapeutics in the 2nd quarter valued at $365,000. Jennison Associates LLC raised its position in ProQR Therapeutics by 1.0% in the 2nd quarter. Jennison Associates LLC now owns 2,981,205 shares of the biopharmaceutical company’s stock valued at $21,763,000 after purchasing an additional 30,831 shares during the last quarter. Finally, Franklin Street Advisors Inc. NC raised its position in ProQR Therapeutics by 50.0% in the 2nd quarter. Franklin Street Advisors Inc. NC now owns 90,000 shares of the biopharmaceutical company’s stock valued at $657,000 after purchasing an additional 30,000 shares during the last quarter. Hedge funds and other institutional investors own 28.55% of the company’s stock.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
Read More: Dividend Aristocrat Index
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.